RxDoctor Payments Data

Prakash Bhatia, MD

Psychiatry · National City, CANPI 1164464137

Payments from drug & device makers

$36,524in general payments, 2019–2025

Across 377 payments — averaging $96.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$22K
  • Johnson & Johnson$8K
  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$786
  • Teva Pharmaceuticals USA, Inc.$778
  • plus $3K from 18 others

What the payments were for

  • Speaking & faculty fees$25,10069%
  • Travel & lodging$1,5024%
  • Food & beverage$9,92127%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,524 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$324,633
Medicare patients
430
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$83,823
VraylarCariprazine Hcl18$24,818
Lurasidone Hcl37$10,041
Aripiprazole94$8,680
Quetiapine Fumarate ErQuetiapine Fumarate26$6,733
Quetiapine Fumarate166$3,559
Divalproex Sodium80$3,518
Divalproex Sodium ErDivalproex Sodium31$1,917
Risperidone124$1,897
Fluvoxamine Maleate18$1,780
Carbamazepine33$1,471
Perphenazine19$1,430
Trazodone Hcl111$1,041
Clomipramine Hcl11$917
Benztropine Mesylate65$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$7,739$83,82327 claims
AbbVieVraylar$1,086$24,81818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in National City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →